SWITZERLAND – Cimeio Therapeutics, a Basel, Switzerland- and Boston, MA-based biotechnology company developing a novel approach to cell therapies, raised $50m in Series A funding.
The round was led by Versant Ventures. Led by CEO Thomas Fuchs, Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ for patients with debilitating and life-threatening diseases. Its proprietary technology platform is based on the discovery of novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders. The company’s initial focus is on a novel approach to hematopoietic stem cell (HSC) transplants and adoptive cell therapy (ACT) and is advancing its first programs towards clinical development in 2023.Cimeio emerged from Versant’s Ridgeline Discovery Engine in Basel, Switzerland.The management includes: 18/04/2022
